1 2 3 4 5 6 7 8 9 10 11 12 13 14
далее c heart failure rat. J. Clin. Invest. 1997; 99: 1500-1505. 46. Martin P. Y. Recent advances in the understanding of water metabolism in heart failure (involvement of aquaporin). Kidney Blood Pressure Res. 2000; 23: 193—194. 47. Xu D., Yin X., Hui Н. et al. Urinary excretion of aquaporin-2 water channel protein in chronic heart failure rats. Chin. Med. J. 2001; 114: 899—901. 48. Wong N. L., Tsiii J. K. Upregulation of vasopressin V2 and aquaporin 2 in the inner medullary collecting duct of cardiomyopathic hamsters is attenuated by enalapril treatment. Metabolism 2002; 51:970-975. 49. Laski М. E., Pressley T. A. Aquaporin mediated water flux as a target for diuretic development. Semin. Nephrol. 1999; 19: 533-550. 50. Ohnishi A., Orita Y., Takagi N. et al. Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men. J. Pharmacol. Exp. Ther. 1995; 272: 546-551. 51. Inoue Т., Ohnishi A., Matsuo A. et al. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis. Clin. Pharmacol. Ther. 1998; 63: 561— 570. 52. Saito Т., Ishikawa S., Abe K. et al. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 im-proves hyponatnemia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH) J Clin Endocnnol Metab 1997, 82 1054—1057 53 Gros P, Palm С The treatment of hyponatraemia using vasopressin antagonists Exp Physiol 2000, 85S 7S—18S 54 Yatsu Т, Tomura Y, Tahara A et al Cardiovascular and renal effects of comvaptan hydrochloride (YM087), a vasopressm VIA and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure Eur J Pharmacol 1999, 376 239— 246 55 Udelson J E, Smith W В, Hendrix С H et al Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure Circulation 2001, 104 2417—2423 56 Martin P-Y, Abraham W Т, Lieming X et al Selective V2receptor vasopressm antagonist decreases urinary aquaponn-2 excretion in patients with chronic heart failure J Am Soc Nephrol 1999, 10 2165—2170 57 Wong L, Verbals J Vasopressin V2 receptor antagonists Cardiovasc Res 2001, 51 391—402 58 Wilkms M R, Redondo J, Brown L A The natnuretic-peptide family Lancet 1997, 349 1307-1310 59 Kaira P R, Anker S D Coats A J S Water and sodium regulation in chronic heart failure the role of natnuretic peptides and vasopressin Cardiovasc Res 2001,51 495—511 60 De Bold A J , Borenstem H B, Veress A T, Sonnenberg H A A rapid and potent natnuretic responce to intravenous injection of atnal myocardial extract in rats Life Sci 1981, 28 89-94 61 Siidoh T, Kangawa К, Mmiammo N , Matsuo H A new natnuretic peptide in porcine brain Nature 1988, 332 78—81 62 Siidoh T, Mmiammo N , Kangawa К, Matsuo H C-type natnuretic peptide (CNP) a new member of the natnuretic peptide family identified in porcine brain Biochem Biophys Res Commun 1990, 168 863—870 63 Suga S, Nakao К, Hosoda К et al Receptor s далее ...